Home Conference Coverage

Conference Coverage

Growing Number of Major Medical Meetings Cancelled – AACR and Others Postponed

The novel coronavirus, also known as COVID19, is prompting major medical societies and healthcare organizations to cancel conferences and...

Sutro Presents Innovative Cancer Therapy Approach Using Tumor Targeted Immunostimulants

A proof of concept for a next-generation dual conjugated combination immunostimulatory antibody-drug conjugate (IADC) was release by Sutro Biopharma,...

Updated Results from Trial Shows Enfortumab Vedotin + Pembrolizumab to Shrink Tumors in the...

Updated findings from EV-103, a phase Ib/II clinical trials of enfortumab vedotin* (Padcev™; Astellas Pharma/Seattle Genetics) in combination with...

Next Generation Immunotherapies

The immune system has already provided a number of potent strategies for treating cancers that are already impacting clinic,...
Featured Image / Photo courtesy 2019: Cambridge Healthtech Institute (CHI)

Bispecific Antibody Evolution for Cancer Therapy: Advances from Merus, Adimab, Regeneron, F-Star, LAVA Therapeutics...

The concept of using bispecific antibodies for tumor therapy has been developed more than 30 years ago with many...
Speakers and attendees during the morning sessions on Wednesday December 11, 2019. during the San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center in San Antonio, TX. This year is the 42nd Anniversary of the meeting where over 7,500 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Photo Courtesy 2019 © MedMeetingImages/Todd Buchanan

SABCS 2019: DESTINY-Breast01 Trial of Trastuzumab Deruxtecan Shows Positive Results in HER2+ Metastatic Breast...

Detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial (NCT03248492) of trastuzumab deruxtecan (DS-8201; fam-trastuzumab deruxtecan in...

ASH 2019: Findings from Phase I Study of IMGN632 Shows Potential in AML and...

New safety and efficacy findings from the dose escalation and expansion of the first-in-human trial of IMGN632 in patients...
Speakers and attendees during Global Capacity Building Showcase at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center on Sunday December 8, 2019. Photo Courtesy 2019 © ASH/Nick Agro

First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of...

Data from a CD117-ADC, an antibody-drug conjugate being developed by Magenta Therapeutics, were presented at the 61st annual meeting...
General Views during at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center. Photo courtesey 2019 © ASH/Danny Morton.

ASH 2019: Brentuximab Vedotin + Nivolumab in Frontline and R/R Hodgkin Lymphoma

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) and nivolumab (Opdivo®; Bristol‑Myers...
Featured Image: American Society of Hematology | Annual Meeting. Courtesy: © 2017. American Society of Hematology. Used with permission.

What to Expect at ASH 2019: Seattle Genetics

With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the...